Reports of Biochemistry
and Molecular Biology
Thu, Dec 25, 2025
[Archive]
Volume 14, Issue 1 (Vol.14 No.1 Apr 2025)
rbmb.net 2025, 14(1): 95-101 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ameer Mahdi N, Choobineh H, Hashim Abdulsalam A, Majidi Z, Dashti* N. Elevated Serum Levels of Galectin-3 and Kidney Injury Molecule-1 as Potential Biomarkers for Early Detection and Staging of Chronic Kidney Disease in Iraqi Population. rbmb.net 2025; 14 (1) :95-101
URL: http://rbmb.net/article-1-1678-en.html
URL: http://rbmb.net/article-1-1678-en.html
Department of Medical Laboratory Science, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Abstract: (748 Views)
Background: Chronic kidney disease (CKD) is a deadly progressive disorder, particularly when it progresses to end-stage renal disease (ESRD). Conventional diagnostic tools such as serum creatinine and estimated glomerular filtration rate (eGFR) often lack sensitivity for early detection of tubular injury. This study aimed to evaluate the diagnostic potential of Galectin-3 (Gal-3) and Kidney Injury Molecule-1 (KIM-1) in Iraqi patients with CKD.
Methods: This case-control study included 150 participants from Baghdad, Iraq, between August 2022 and May 2023. Participants were categorized into three groups: healthy controls (n=50), mild CKD (n=50), and severe CKD (n=50). Serum levels of Gal-3 and KIM-1 were measured using ELISA kits. Demographic, clinical, and biochemical data were collected, including age, sex, BMI, diabetes status, hypertension, and eGFR. Statistical analyses included ANOVA, Kruskal-Wallis test, and correlation analysis.
Results: Gal-3 levels were significantly higher in CKD patients compared to healthy controls, showing a progressive increase from mild to severe CKD stages (P < 0.001). It was also associated with systemic factors such as diabetes mellitus, hypertension, and obesity. In contrast, KIM-1 levels were elevated primarily in patients with advanced CKD or ESRD (P = 0.036), but no significant difference was observed between control and mild CKD groups (P = 0.149). KIM-1 did not show consistent correlations with traditional markers of renal function, suggesting its specificity for structural tubular damage rather than functional decline.
Conclusions: Our findings suggest that Gal-3 may serve as a broader biomarker reflecting both systemic inflammation and fibrosis, while KIM-1 appears to be more specific to advanced renal injury.
Methods: This case-control study included 150 participants from Baghdad, Iraq, between August 2022 and May 2023. Participants were categorized into three groups: healthy controls (n=50), mild CKD (n=50), and severe CKD (n=50). Serum levels of Gal-3 and KIM-1 were measured using ELISA kits. Demographic, clinical, and biochemical data were collected, including age, sex, BMI, diabetes status, hypertension, and eGFR. Statistical analyses included ANOVA, Kruskal-Wallis test, and correlation analysis.
Results: Gal-3 levels were significantly higher in CKD patients compared to healthy controls, showing a progressive increase from mild to severe CKD stages (P < 0.001). It was also associated with systemic factors such as diabetes mellitus, hypertension, and obesity. In contrast, KIM-1 levels were elevated primarily in patients with advanced CKD or ESRD (P = 0.036), but no significant difference was observed between control and mild CKD groups (P = 0.149). KIM-1 did not show consistent correlations with traditional markers of renal function, suggesting its specificity for structural tubular damage rather than functional decline.
Conclusions: Our findings suggest that Gal-3 may serve as a broader biomarker reflecting both systemic inflammation and fibrosis, while KIM-1 appears to be more specific to advanced renal injury.
Keywords: Biomarker, Chronic kidney disease, Galectin-3, Kidney Injury Molecule-1, Renal tubular injury, Serum biomarkers.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2025/05/26 | Accepted: 2025/09/13 | Published: 2025/12/9
Received: 2025/05/26 | Accepted: 2025/09/13 | Published: 2025/12/9
References
1. Shawky SA, Gaber O, Mostafa E, Sarhan WM. Uncoupling protein 2 expression modulates obesity in chronic kidney disease patients. Rep Biochem Mol Biol. 2021;10(1):119-125. [DOI:10.52547/rbmb.10.1.119] [PMID] []
2. Badro DA. Chronic kidney disease management in developing countries. Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research. Springer; Cham2023: 1-146. [DOI:10.1007/978-3-030-74786-2_27-1]
3. Deng L, Guo S, Liu Y, Zhou Y, Liu Y, Zheng X, et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health. 2025;25(1):636. [DOI:10.1186/s12889-025-21851-z] [PMID] []
4. Nabatchian F, Zand P, Taraghikhah A, Sharifpour T. Kidney injury molecule-1 (KIM-1) a potential biomarker for early detection of AKI in neonates. Lab Diag. 2025;16(66):41-9.
5. Horiuchi Y, Wettersten N, Van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, et al. Galectin-3, acute kidney injury and myocardial damage in patients with acute heart failure. J Card Fail. 2023;29(3):269-77. [DOI:10.1016/j.cardfail.2022.09.017] [PMID] []
6. Grujcic M, Milovanovic M, Nedeljkovic J, Jovanovic D, Arsenijevic D, Solovjova N, et al. The Possible Effects of Galectin-3 on Mechanisms of Renal and Hepatocellular Injury Induced by Intravascular Hemolysis. Int J Mol Sci. 2024;25(15):8129. [DOI:10.3390/ijms25158129] [PMID] []
7. Jana S, Mitra P, Roy S. Proficient novel biomarkers guide early detection of acute kidney injury: a review. Diseases 2022; 11(1): 8. [DOI:10.3390/diseases11010008] [PMID] []
8. Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit care. 2013;17(1):204. [DOI:10.1186/cc11454] [PMID] []
9. Iordan L, Gaita L, Timar R, Avram V, Sturza A, Timar B. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)-A Narrative Review. Int J Mol Sci. 2024;25(13):7057. [DOI:10.3390/ijms25137057] [PMID] []
10. Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis. 2021;77(1):110-21. [DOI:10.1053/j.ajkd.2020.04.017] [PMID]
11. Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yamahara M, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell metab. 2020;32(3):404-19. e6. [DOI:10.1016/j.cmet.2020.06.020] [PMID]
12. Safaie N, Masoumi S, Alizadeh S, Mirzajanzadeh P, Nejabati HR, Hajiabbasi M, et al. SGLT2 inhibitors and AMPK: The road to cellular housekeeping? Cell Biochem Funct. 2024;42(1):e3922. [DOI:10.1002/cbf.3922] [PMID]
13. Yazdani Y, Zamani AR, Majidi Z, Sharafkandi N, Alizadeh S, Mofrad AM, et al. Curcumin and targeting of molecular and metabolic pathways in multiple sclerosis. Cell Biochem Funct. 2023;41(7):779-87. [DOI:10.1002/cbf.3841] [PMID]
14. Al-Rawi KF, Ali HH, Guma MA, Aldahham BJM, Alaaraji SFT, Al-Ani O, Tariq Ali A. Relationship between IL-2, IL-17 concentrations, and serum creatinine levels in men with chronic kidney diseases. Rep Biochem Mol Biol. 2022;10(4):664-674 [DOI:10.52547/rbmb.10.4.664] [PMID] []
15. Safaie N, Idari G, Ghasemi D, Hajiabbasi M, Alivirdiloo V, Masoumi S, et al. AMPK activation; a potential strategy to mitigate TKI-induced cardiovascular toxicity. Arch Physiol Biochem. 2024:131(3):329-41. [DOI:10.1080/13813455.2024.2426494] [PMID]
16. Majidi Z, Hosseinkhani S, Amiri-Dashatan N, Emamgholipour S, Tutunchi S, Hashemi J, et al. Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials. J Investig Med. 2021;69(3):697-703. [DOI:10.1136/jim-2020-001588] [PMID]
17. Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018;93(1):252-9. [DOI:10.1016/j.kint.2017.06.028] [PMID] []
18. Decleves A-E, Mathew AV, Cunard R, Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol. 2011;22(10):1846-55. [DOI:10.1681/ASN.2011010026] [PMID] []
19. Jimba T, Kaneko H, Suzuki Y, Okada A, Azegami T, Ko T, et al. Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2025, 13;11(2):155-163. [DOI:10.1093/ehjcvp/pvae094] [PMID] []
20. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. [DOI:10.1056/NEJMoa1504720] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
